Aligos Therapeutics, Inc. (ALGS) stock
ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3010% below fair value
$2.16−0.41 (-15.95%)
Close on Nov 11, 2026Market cap $26.98MP/E –Yield –
Aligos Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Aligos Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -1244.2%. For fiscal 2025 it was -4024.9%, against -2469.0% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -4024.9% | −1556.0 |
| FY2024 | Dec 31, 2024 | -2469.0% | −1045.5 |
| FY2023 | Dec 31, 2023 | -1423.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -773.5% | +1150.5 |
| Q1 FY2026 | Mar 31, 2026 | -951.6% | +5235.9 |
| Q4 FY2025 | Dec 31, 2025 | -12907.7% | −9514.5 |
| Q3 FY2025 | Sep 30, 2025 | -3827.4% | −2216.9 |
| Q2 FY2025 | Jun 30, 2025 | -1924.0% | +565.5 |
| Q1 FY2025 | Mar 31, 2025 | -6187.5% | −3010.8 |
| Q4 FY2024 | Dec 31, 2024 | -3393.2% | +475.4 |
| Q3 FY2024 | Sep 30, 2024 | -1610.5% | +147.2 |
| Q2 FY2024 | Jun 30, 2024 | -2489.5% | −2043.8 |
| Q1 FY2024 | Mar 31, 2024 | -3176.7% | +13907.6 |
| Q4 FY2023 | Dec 31, 2023 | -3868.6% | – |
| Q3 FY2023 | Sep 30, 2023 | -1757.7% | – |
| Q2 FY2023 | Jun 30, 2023 | -445.8% | – |
| Q1 FY2023 | Mar 31, 2023 | -17084.3% | – |
See a number that looks wrong?